Summary
Cadence Design Systems, Inc. (CDNS) announced the completion of its acquisition of OpenEye Scientific Software Inc. on August 31, 2022. This strategic move integrates OpenEye's advanced computational molecular modeling and simulation software, crucial for drug discovery in the pharmaceutical and biotech sectors, into Cadence's existing offerings. The acquisition was financed through a mix of existing cash reserves and draws from its senior unsecured revolving credit facility.
Key Highlights
- 1Cadence Design Systems has acquired OpenEye Scientific Software Inc.
- 2OpenEye specializes in computational molecular modeling and simulation software for drug discovery.
- 3The acquisition targets the pharmaceutical and biotech industries.
- 4The transaction was completed on August 31, 2022.
- 5Funding for the acquisition came from cash on hand and credit facility borrowings.
- 6This acquisition expands Cadence's capabilities in life sciences and drug discovery markets.
Frequently Asked Questions
The acquisition of OpenEye Scientific Software allows Cadence to significantly enhance its presence in the rapidly growing life sciences market, particularly in drug discovery. By integrating OpenEye's specialized molecular modeling and simulation software, Cadence can offer more comprehensive solutions to pharmaceutical and biotech companies.
The acquisition was financed using a combination of Cadence's existing cash on hand and borrowings made under its senior unsecured revolving credit facility.
OpenEye Scientific Software is a leading provider of computational molecular modeling and simulation software. This technology is vital for pharmaceutical and biotech companies engaged in the process of discovering new drugs.
The acquisition was completed on August 31, 2022.